Astrazeneca Ab

Peter William Rodney Caulkett

Roger James

Rodney Brian Hargreaves

Craig Johnstone

Clifford David Jones

Michael Howard Block

Scott Boyd

Suzanne Saxon Bowker

Darren McKerrecher

Darren Mckerrecher

Gordon Stuart Currie

Barry Raymond Hayter

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Compounds effecting glucokinase

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes.  The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

The invention relates to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R, R, R, n and m are described in the specification, useful in the treatment of  a disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

Vinyl phenyl derivatives as GLK activators

Growing community of inventors

Cheshire, United Kingdom

Peter William Rodney Caulkett